Suppr超能文献

骨髓移植后显著的酶尿症:与静脉闭塞性疾病诱发的“肝肾综合征”相关

Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced "hepatorenal syndrome".

作者信息

Fink J C, Cooper M A, Burkhart K M, McDonald G B, Zager R A

机构信息

Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.

出版信息

J Am Soc Nephrol. 1995 Dec;6(6):1655-60. doi: 10.1681/ASN.V661655.

Abstract

During the first month after bone marrow transplantation, approximately 15% of patients develop acute renal failure (ARF). This usually occurs in the setting of hepatic veno-occlusive disease (VOD). Prior clinical data have suggested that this form of ARF has a hemodynamic basis, analogous to the hepatorenal syndrome (HRS). If so, then proximal tubular injury would not be expected. To directly test this hypothesis, enzymuria (N-acetyl-beta-D-glucosaminidase [NAG]) was quantitated in the following groups of patients within the first 35 days after BMT: (1) VOD+ARF (serum creatinine level > 1.5 mg/dL; N = 10); (2) VOD with relatively normal renal function (serum creatinine level < 1.5 mg/dL; N = 11); and (3) patients without hepatic or renal complications (BMT controls; N = 12). For comparison, NAG was also quantitated in the following groups of non-BMT patients: (1) toxic/ischemic acute tubular necrosis (ATN) (N = 10); (2) jaundice without azotemia (N = 5); and (3) HRS (N = 6). Urine samples from eight healthy subjects established normal NAG concentrations (2.5 +/- 0.5 microU/mg urinary creatinine; mean +/- SE). All non-BMT patients with ATN had markedly elevated NAG levels (61 +/- 12; P < 0.001), validating the test as a marker of tubular damage. NAG concentrations were significantly elevated in all of the control BMT patients (24 +/- 3; P < 0.01), and the presence of VOD was associated with further striking increments (approximately 50 times normal). However, the degree of enzymuria was virtually identical for VOD patients with (125 +/- 27) and without (122 +/- 17) ARF. Jaundice in a non-BMT setting was associated with only mild NAG elevations (11 +/- 2). However, striking enzymuria was noted in all HRS patients (61 +/- 20), equaling the levels seen with ATN. The following conclusions were derived: (1) subclinical tubular injury, as defined by enzymuria, appears to be ubiquitous after BMT; (2) VOD dramatically increases the extent of enzymuria; (3) the degree of enzymuria in VOD patients is not correlated with renal dysfunction, implying that the associated ARF has a large hemodynamic component; and (4) HRS and ATN manifest comparable degrees of enzymuria, suggesting that substantial tubular damage exists in both of these forms of ARF.

摘要

在骨髓移植后的第一个月内,约15%的患者会发生急性肾衰竭(ARF)。这通常发生在肝静脉闭塞性疾病(VOD)的背景下。先前的临床数据表明,这种形式的ARF有血流动力学基础,类似于肝肾综合征(HRS)。如果是这样,那么预计不会出现近端肾小管损伤。为了直接验证这一假设,在骨髓移植后的前35天内,对以下几组患者的酶尿(N-乙酰-β-D-氨基葡萄糖苷酶[NAG])进行了定量:(1)VOD+ARF(血清肌酐水平>1.5mg/dL;N=10);(2)肾功能相对正常的VOD患者(血清肌酐水平<1.5mg/dL;N=11);以及(3)无肝脏或肾脏并发症的患者(骨髓移植对照组;N=12)。为了进行比较,还对以下几组非骨髓移植患者的NAG进行了定量:(1)中毒/缺血性急性肾小管坏死(ATN)(N=10);(2)无氮质血症的黄疸患者(N=5);以及(3)肝肾综合征(N=6)。来自8名健康受试者的尿液样本确定了正常的NAG浓度(2.5±0.5微单位/毫克尿肌酐;平均值±标准误)。所有患有ATN的非骨髓移植患者的NAG水平均显著升高(61±12;P<0.001),证实该检测可作为肾小管损伤的标志物。所有骨髓移植对照患者的NAG浓度均显著升高(24±3;P<0.01),VOD的存在与进一步显著升高相关(约为正常水平的50倍)。然而,有ARF的VOD患者(125±27)和无ARF的VOD患者(122±17)的酶尿程度几乎相同。非骨髓移植情况下的黄疸仅与NAG轻度升高相关(11±2)。然而,所有肝肾综合征患者均出现显著的酶尿(61±20),与ATN患者的水平相当。得出以下结论:(1)以酶尿定义的亚临床肾小管损伤在骨髓移植后似乎普遍存在;(2)VOD显著增加了酶尿的程度;(3)VOD患者的酶尿程度与肾功能不全无关,这意味着相关的ARF有很大的血流动力学成分;(4)肝肾综合征和ATN表现出相当程度的酶尿,表明这两种形式的ARF均存在实质性的肾小管损伤。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验